The Supreme Court ruled 6-3 against President Trump’s use of emergency powers to impose tariffs, impacting drug imports. This decision affects hospital leaders and pharmaceutical manufacturers relying on global supply chains. The ruling limits the administration’s use of the International Emergency Economic Powers Act, which was previously leveraged to impose tariffs. The immediate consequence is…

Pharmaceutical companies, including major players like Pfizer and Merck, are preparing legal arguments against President Trump’s Medicare drug pricing pilot programs, which aim to reduce drug costs by up to 30% for seniors. These initiatives, announced in July 2025, could significantly impact the pharmaceutical industry, potentially affecting billions of dollars in revenue. The Trump administration’s…

Saliva tests, easier to collect than blood samples, show promise in detecting diseases like cavities, infections, and cancer. Despite their potential, these tests face obstacles such as high costs and lack of insurance coverage. Currently, only HIV and COVID-19 saliva tests have FDA approval. However, new Medicare incentives for FDA-approved tests could drive companies to…

The FDA has reversed its decision and agreed to review Moderna’s mRNA flu vaccine, just a week after initially rejecting it due to trial design concerns. This reconsideration is significant as it could lead to the first mRNA-based flu vaccine, following the success of mRNA COVID-19 vaccines. Moderna aims for full approval for adults aged…

New Medicaid work requirements, set to take effect in January 2026, will significantly impact middle-aged adults, especially women aged 50 to 64. Approximately 20m low-income Americans across 42 states and Washington, D.C., will be required to meet specific work activity benchmarks to retain their coverage. Critics, including the Center on Budget and Policy Priorities, argue…

Florida’s AIDS Drug Assistance Program (ADAP) is facing significant funding cuts, potentially affecting 16,000 residents. The proposed changes would lower the income eligibility from 400% to 130% of the federal poverty level, risking a $120m shortfall. This move, driven by the administration of Governor Ron DeSantis, has been temporarily halted due to legal challenges. Experts…